JP2015028094A5 - - Google Patents

Download PDF

Info

Publication number
JP2015028094A5
JP2015028094A5 JP2014231788A JP2014231788A JP2015028094A5 JP 2015028094 A5 JP2015028094 A5 JP 2015028094A5 JP 2014231788 A JP2014231788 A JP 2014231788A JP 2014231788 A JP2014231788 A JP 2014231788A JP 2015028094 A5 JP2015028094 A5 JP 2015028094A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
oral
layer
zaleplon
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014231788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015028094A (ja
JP6104873B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015028094A publication Critical patent/JP2015028094A/ja
Publication of JP2015028094A5 publication Critical patent/JP2015028094A5/ja
Application granted granted Critical
Publication of JP6104873B2 publication Critical patent/JP6104873B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014231788A 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム Expired - Fee Related JP6104873B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12005108P 2008-12-04 2008-12-04
US61/120,051 2008-12-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011539117A Division JP2012510987A (ja) 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム

Publications (3)

Publication Number Publication Date
JP2015028094A JP2015028094A (ja) 2015-02-12
JP2015028094A5 true JP2015028094A5 (enExample) 2015-12-10
JP6104873B2 JP6104873B2 (ja) 2017-03-29

Family

ID=42232930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539117A Pending JP2012510987A (ja) 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム
JP2014231788A Expired - Fee Related JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011539117A Pending JP2012510987A (ja) 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム

Country Status (11)

Country Link
US (2) US9693981B2 (enExample)
EP (1) EP2378883B1 (enExample)
JP (2) JP2012510987A (enExample)
KR (1) KR20110116004A (enExample)
CN (1) CN102300463B (enExample)
CA (1) CA2745741A1 (enExample)
ES (1) ES2562925T3 (enExample)
IL (1) IL213376A (enExample)
PL (1) PL2378883T3 (enExample)
WO (2) WO2010064139A2 (enExample)
ZA (1) ZA201104620B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2874737A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
WO2014039951A1 (en) * 2012-09-10 2014-03-13 Novartis Ag Enteral pharmaceutical compositions
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3043779B1 (en) 2013-09-13 2018-05-16 R.P. Scherer Technologies, LLC Encased-pellet tablets
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
MX2016016406A (es) 2014-06-11 2017-10-12 Massachusetts Inst Technology Estructuras de permanencia, y métodos relacionados.
WO2016109412A1 (en) * 2014-12-29 2016-07-07 Boston Scientific Scimed, Inc. Compositions, devices and methods for multi-stage release of chemotherapeutics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
RU2019103297A (ru) * 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
CA3060026A1 (en) * 2017-04-18 2018-10-25 Jayant Jagannath Khandare Polymer based formulation for release of drugs and bioactives at specific git sites
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
TWI811221B (zh) 2017-06-09 2023-08-11 美商萊恩卓治療公司 具有釋放速率調節膜之胃的滯留系統
EP3705118B1 (en) 2017-10-31 2024-02-14 Samyang Holdings Corporation Oral solid dosage form composition having improved disintegration and preparation method therefor
IL286512B2 (en) * 2019-03-20 2026-03-01 Lyndra Therapeutics Inc Capsules and capsule coatings for stomach-retaining dosage forms
CN113840596A (zh) * 2019-03-20 2021-12-24 林德拉治疗公司 用于胃滞留剂型的衣层
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
US11491125B1 (en) * 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations
IL314378A (en) * 2022-01-19 2024-09-01 Lyndra Therapeutics Inc Dosage forms for gastric preservation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH07179334A (ja) * 1993-12-22 1995-07-18 Sanei Touka Kk カプセル及びカプセル剤の製造方法
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
BR0211317A (pt) 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
US20080081834A1 (en) * 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
KR100553887B1 (ko) * 2003-06-24 2006-02-24 삼성전자주식회사 수직 및 수평으로 광시야각을 갖는 영상표시용 스크린 및이를 구비하는 프로젝션 텔레비전
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
JP2007510733A (ja) 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用
EP1535952B1 (en) * 2003-11-28 2013-01-16 Universite Louis Pasteur Method for preparing crosslinked polyelectrolyte multilayer films
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
JP4756835B2 (ja) * 2004-07-14 2011-08-24 キヤノン株式会社 生化学反応カートリッジ
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1973421A2 (en) * 2005-12-23 2008-10-01 Cadbury Adams USA LLC Compositions providing a sensation substantially similar to that provided by menthol
DK2997953T3 (en) 2006-01-18 2019-04-15 Intec Pharma Ltd ADMINISTRATION ORAL ADMINISTRATION
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CA2674610C (en) * 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment

Similar Documents

Publication Publication Date Title
JP2012510987A5 (enExample)
JP6815358B2 (ja) 時限パルス放出システム
CN102300463B (zh) 扎来普隆(zaleplon)胃滞留药物传递系统
JP2018536007A5 (enExample)
JP2011519967A5 (enExample)
Zema et al. Gastroresistant capsular device prepared by injection molding
JP2007528901A5 (enExample)
JP7041333B2 (ja) 放出調節コーティングカプセル
JP2016525572A5 (enExample)
TW200936186A (en) Pharmaceutical formulations
JP2016539953A5 (enExample)
JP7041334B2 (ja) 放出調節コーティングカプセル
JP2018536007A (ja) 胃保持性装置
HK1209337A1 (en) Medicament-containing hollow particle
ES2546172T3 (es) Forma de dosificación para la liberación modificada de betahistina
EP3866758B1 (en) Softgels with solid or gel-like polymeric fill matrix
JP5698683B2 (ja) 治療薬のパルス放出組成物
JP6294457B2 (ja) 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
HK1214136A1 (zh) 硝酸氨基烷基酯的延长释放组合物
JP2017530990A (ja) 口腔粘膜フィルム製剤
Benzine Enzymatically triggered polymeric drug delivery systems for colon targeting
CN103735528B (zh) 盐酸曲美他嗪双层渗透泵控释片及制备方法
EP2874611B1 (en) Gastro-resistant delayed release pharmaceutical form
JP2018172363A (ja) 腸溶性組成物中に含まれる薬物塩の溶出性を改善する方法
Garapati et al. Tailoring the Release of Drugs Using Excipients